key: cord-0889283-zh50tc3k
authors: Isaeva, Olga I.; Ketelaars, Steven L.C.; Kvistborg, Pia
title: In silico analysis predicts a limited impact of SARS-CoV-2 variants on CD8 T cell recognition
date: 2022-03-23
journal: bioRxiv
DOI: 10.1101/2022.03.23.485487
sha: d06be4324b8e4a0ade208cc10112bf58a7637e08
doc_id: 889283
cord_uid: zh50tc3k

Since the start of the COVID-19 pandemic, mutations have led to the emergence of new SARS-CoV-2 variants, and some of these have become prominent or dominant variants of concern. This natural course of development can have an impact on how protective the previously naturally or vaccine induced immunity is. Therefore, it is crucial to understand whether and how variant specific mutations influence host immunity. To address this, we have investigated how mutations in the recent SARS-CoV-2 variants of interest and concern influence epitope sequence similarity, predicted binding affinity to HLA, and immunogenicity of previously reported SARS-CoV-2 CD8 T cell epitopes. Our data suggests that the vast majority of SARS-CoV-2 CD8 T cell recognized epitopes are not altered by variant specific mutations. Interestingly, for the CD8 T cell epitopes that are altered due to variant specific mutations, our analyses show there is a high degree of sequence similarity between mutated and reference SARS-CoV-2 CD8 T cell epitopes. However, mutated epitopes, primarily derived from the spike protein, in SARS-CoV-2 variants Delta, AY.4.2 and Mu display reduced predicted binding affinity to their restriction element. These findings indicate that the recent SARS-CoV-2 variants of interest and concern have limited ability to escape memory CD8 T cell responses raised by vaccination or prior infection with SARS-CoV-2 early in the pandemic. The overall low impact of the mutations on CD8 T cell cross-recognition is in accordance with the notion that mutations in SARS-CoV-2 are primarily the result of receptor binding affinity and antibody selection pressures exerted on the spike protein, unrelated to T cell immunity.

Introduction 37

The COVID-19 pandemic caused by SARS-CoV-2 is having a global catastrophic impact on public 38 health and social economy (1, 2) . SARS-CoV-2 was first identified in humans in late 2019 in Wuhan, 39 China, and the outbreak was designated as a pandemic by the WHO on March 11th, 2020 (3,4). The 40 early variant of SARS-CoV-2 (also known as lineage B or Wuhan-Hu-1; UniProt: UP000464024; 41

Genome accession: MN908947) is hereafter referred to as 'reference SARS-CoV-2'. 42 SARS-CoV-2 is a single-stranded RNA virus characterized by an inherently high mutation rate, short 43 replication time and high virion yield (5-8). As the virus spreads, this leads to a high genetic 44 diversity and allows the virus to evolve rapidly as a result of natural selection pressures, including 45 those originating from the host immune system. Mutations accumulate over time and result in amino 46 acid changes that decrease the antigenicity of immune targeted proteins. This gradual change in 47

antigenicity of viral proteins, driven by selective immune pressure, is known as antigenic drift (9). 48

Antigenic drift allows viruses to continuously evade host immunity, facilitating recurrent viral 49 outbreaks. In acute infectious disease, antigenic drift is primarily driven by antibody responses 50 leading to selection of escape mutants (9). In accordance with this, many of the amino acid changes 51

in SARS-CoV-2 variants are located in the spike protein, the main target of neutralizing antibodies 52 (10). These antibodies form the only immune mechanism that is able to provide sterilizing immunity, 53

preventing host cells from being infected. The rate of evolution of the SARS-CoV-2 spike protein is 54 much higher than that of similar proteins in other known viruses that cause acute infectious disease in 55

humans. For example, its rate of evolution is approximately 10-fold higher than the evolution rate of 56 the influenza A hemagglutinin and neuraminidase proteins (9). In addition, a large number of amino 57 acid changes have accumulated in SARS-CoV-2 proteins that are not known antibody targets (11). 58

These amino acid changes may have inferred a fitness advantage to the virus unrelated to antibody 59 immunity, as antigenic drift is primarily driven by antibody responses in acute viral infections 60 (6,9,12,13). 61

Even though T cells are unlikely to be a main source to antigenic drift there is ample evidence for the 62 importance of these cells in protection against severe and critical COVID-19 and re-infections: 1) 63

Depletion of CD8 T cells led to impaired clearance of SARS-CoV-2 in a COVID-19 mouse model 64 (14) and breakthrough infections in a rhesus macaque model upon rechallenge; 2) Lower baseline 65

peripheral blood CD8 T cell counts have been shown to correlate with decreased patient survival 66 (15, 16) ; and 3) CD8 T cells have also been shown to impact COVID- 19 infections by February 2022 ( Figure 1A , (22) ). There is accumulating evidence that recent SARS-84

CoV-2 variants including Beta, Delta and Omicron are less efficiently neutralized by vaccine 85 recipients' sera (23,24). In terms of T cell immunity, there is experimental data by other groups 86

showing that T cell responses induced by reference SARS-CoV-2 generally cross-recognize SARS-87

CoV-2 variants Alpha, Beta, Gamma, Delta and Omicron (25-29). However, these papers do not 88 include systematic data regarding the effect of SARS-CoV-2 variant-specific amino acid changes on 89 the properties of previously recognized CD8 T cell epitopes. 90

In this work, we investigate the potential consequences of variant specific mutations on the SARS-91

CoV-2 specific CD8 T cell responses raised by either natural infection or vaccination based on in 92 silico analysis. In particular, we explore changes in predicted binding affinity of the epitopes to their 93 HLA restriction elements, predicted immunogenicity and likelihood of CD8 T cell receptor cross-94 recognition of epitopes between the reference SARS-CoV-2 strain and SARS-CoV-2 variants of 95 interest and concern. We perform these analyses pan-proteome to identify the degree of protection 96 after a natural infection. Furthermore, the vaccines currently approved by WHO are limited to the 97 spike protein (30) . Therefore, we have also conducted the analyses focused on CD8 T cell recognized 98 epitopes derived from the spike protein only to determine the degree of the vaccine-mediated 99 protection. 100

Materials and methods 101

The list of SARS-CoV-2 variants of interest and variants of concern has been compiled according to 103 the WHO 

The normalized epitope similarity score between the altered and reference SARS-CoV-2 CD8 T cell 118 recognized epitope was calculated as described by Frankild et al. (35) . This method does not allow 119 the calculation of the similarity score between two sequences of differing lengths. For this reason, we 120 have set the sequence similarity score of CD8 T cell recognized epitopes harboring deletions and/or 121 insertions to 0. IEDB's epitope cluster analysis tool was additionally used on each reference and 122 altered epitope to determine if the epitope pairs share a sequence identity of 80%, 80-90% or more 123 than 90% (36). The parameters used were: minimum sequence identity threshold: 80%, 90%. 124

Minimum/Maximum peptide length: NA. Clustering method: fully interconnected clusters (cliques). 125 IEDB's T cell class I pMHC immunogenicity prediction tool was used to compare the 126 immunogenicity of the altered and reference SARS-CoV-2 CD8 T cell recognized epitopes (37). The 127

default setting was used, masking the 1st, 2nd and C-terminus amino acids of the epitopes in the 128 analysis. 129

For all parsed reference SARS-CoV-2 CD8 T cell recognized epitopes with experimentally validated 130 HLA restriction information, the predicted binding affinity to the given HLA was calculated for both 131 the reference and altered epitope using NetMHCpan-4.1 (38). The predicted binding affinity is 132 expressed as the half-maximal inhibitory concentration IC50 nM. For each paired reference and 133 altered epitope, the fold change in predicted binding affinity as a result of the mutation(s) was 134 calculated. A 2-fold change in predicted binding affinity was defined as a decrease in predicted 135 binding affinity, a fold change below 0.5 as an increase in predicted binding affinity and a fold 136 change between 0.5 and 2 was conservatively defined as neutral. CD8 T cell recognized epitopes 137 overlapping with a deletion and/or insertion and not predicted to bind to the HLA as a result of the 138 mutation were defined as decreased in predicted binding affinity. 139

For all analyzed SARS-CoV-2 CD8 T cell recognized reference and altered epitope pairs, differences 141 in predicted immunogenicity and predicted binding affinity were assessed using a two-tailed 142

Wilcoxon matched-pairs signed rank test. The increase in fractions of CD8 T cell recognized epitopes 143 with decreased binding affinity and/or an epitope sequence similarity <85% was also assessed using a 144 two-tailed Wilcoxon matched-pairs signed rank test. Comparisons in log2 fold change predicted 145 binding affinity and/or epitope sequence similarity between spike and non-spike protein-derived 146 mutated CD8 T cell recognized epitopes were assessed using a two-tailed Mann-Whitney U test. 147

Differences were considered significant if P < 0.05. Statistical analysis was performed with 148

GraphPad Prism (version: 8.4.2, for Windows, GraphPad Software, San Diego, California USA, 149

(39)). 150 3

Results 151

Variants of Concern and Interest 153

We focused our analysis on the current SARS-CoV-2 variants of concern (VOC) (Alpha, B. these with the sequences spanning the identified non-synonymous mutations in the investigated 162 SARS-CoV-2 variants ( Figure 1B) . Specifically, all SARS-CoV-2 CD8 T cell epitopes detected in 163 patients with COVID-19 were included. Epitopes deduced from peptide pools, in which the exact 164 reactive peptide is not validated, were filtered out. In addition, studies conducted in the adoptive 165 transfer setting were filtered out. 166

The vast majority of the 973 included CD8 T cell recognized epitopes was found to be conserved 167 across the different variants (median: 97.8%, range: 96.5-98.3%): we identified a total of 93 unique 168 epitopes that harbored one or more mutations ( Figure 1C ). Specifically, between 17 and 34 unique 169 epitopes per variant (median: 21) overlap with one or more amino acid substitutions, deletions and/or 170 insertions ( Figure 1D , Supplementary Tables 2 and 3) . Six CD8 T cell recognized epitopes were 171 considered eliminated in SARS-CoV-2 variant Alpha as they were located downstream of a stop-172 codon mutation (ORF8 Q27*); three additional epitopes contain a deletion (S∆69/70 or Tables 2 and 3 ). In total, these epitopes bind 191

27 HLA alleles, with between 1 and 14 epitopes per allele (median: 3, Figure S1A ). 192

CoV-2 CD8 T cell recognized epitopes 194

Amino acid changes in SARS-CoV-2-derived CD8 T cell epitopes can reduce the sequence similarity 195

to the reference epitope. The more distinct the biochemical properties of an amino acid substitution 196 are compared to the reference amino acid, the greater the dissimilarity. This could lead to reduced or 197 abrogated activation of memory CD8 T cells reacting to the altered epitope. The epitope sequence 198 similarity of the altered epitope to the reference epitope can therefore be used as an in silico proxy for 199 likelihood of T cell receptor cross-recognition. 200

To test the epitope sequence similarity between the variant-specific and matched reference epitopes, 201

we conducted two analyses: 1) We compared the sequence similarity between the reference and the 202 altered epitopes using a previously published method (35). Importantly, this method incorporates the 203 biochemical properties of amino acid substitutes to score the epitope sequence similarity, which is 204 crucial in epitope cross-recognition by CD8 T cell receptors. Experimental data demonstrate that 205 CD8 T cell receptor recognition drops to 50% if peptide similarity drops below 85% (42) . We found 206 that the vast majority (median: 90%, range: 65-100%) of the reference and the matched variant 207 specific CD8 T cell epitopes share over 85% sequence similarity (Figure 2A and S2A) . 2) In 208 addition, we measured the degree of sequence similarity between the pairs of epitopes using the 209 IEDB clustering tool which performs a local alignment (36). In contrast to the first method, the IEDB 210 clustering tool allows comparison of epitopes of differing lengths (e.g. due to insertions/deletions). 211

Data from our previous experiments in the tumor setting suggests that a sequence similarity above 212 80% could serve as an indicator of potential TCR cross-reactivity (43,44). The majority (median: 213 93%, range: 73-100%) of reference SARS-CoV-2 epitopes and variant derived epitopes share at least 214 80% similarity ( Figure S2B ). Taken together, these in silico analyses suggest that the ability of 215 memory CD8 T cells, induced by natural infection with the reference virus, to respond to the 216 included variants is not significantly impaired. 217

The likelihood that a certain peptide is immunogenic can be predicted based on the presence and, 218

importantly, positioning of amino acids with certain biochemical properties (37). To investigate 219

whether a SARS-CoV-2 CD8 T cell recognized epitope is predicted to be more or less immunogenic 220 as a result of an amino acid change, we applied the IEDB T cell class I pMHC immunogenicity 221 prediction tool to the set of reference SARS-CoV-2 CD8 T cell recognized epitopes and variant 222 derived epitopes. This tool uses a large set of known peptide immunogenicity values to 223 computationally predict whether CD8 T cell epitopes are immunogenic (i.e., likelihood for T cell 224 recognition) or not (37). Surprisingly, the epitopes derived from the Omicron and Lambda variants 225

were predicted to be significantly more and less immunogenic, respectively (Omicron: p=0.0042, 226

(Lambda: p=0.03; Figure 2B ). For all included SARS-CoV-2 variants, a large fraction of mutated 227 epitopes was predicted to be either more immunogenic (median: 47%, range: 11-57%) or unchanged 228 in immunogenicity (median: 28%, range: 19-44%). Between 6% and 44% (median: 24%) of variant 229 specific CD8 T cell recognized epitopes were predicted to be less immunogenic as a result of the 230 mutation ( Figure S3A ). Taken together, these analyses indicate that there is a high degree of 231 sequence similarity between altered and reference epitopes in all analyzed SARS-CoV-2 variants, 232

which is likely to result in a high degree of CD8 T cell cross-reactivity between these epitopes. CD8 T cell recognized epitopes with previously experimentally validated HLA restriction elements. 240 We used the NetMHCpan-4.1 tool to predict the binding affinity of each reference and variant 241 specific CD8 T cell epitope to the matched HLA restriction element (38). In this analysis, epitopes 242 that can bind to more than one HLA allele were included for each of the HLA allele they bind to. 243

For each included SARS-CoV-2 variant, we observed decreased binding affinity, defined as a ≥ 2-fold 244 change in IC50 value for a subset of the variant specific epitopes (median 37% of epitopes, range: 245 21%-50%) ( Figure 2C ). Between 41% and 64% (median: 50%) of variant specific epitopes retained 246 their predicted binding affinity (neutral; 0.5< fold change in IC50 <2), and for between 0% and 25% 247

(median: 12%) of altered epitopes an increased binding affinity was predicted (≤0.5-fold change in 248 IC50 value). Following a comparison of the difference in predicted binding affinity of the paired 249 reference SARS-CoV-2 CD8 T cell recognized epitopes and mutated epitopes, the small set of 250 epitopes of the Delta variant and its subvariant AY.4.2 were predicted to have a significantly reduced 251

binding affinity to the HLA as a result of their mutations (Delta: p=0.01, AY.4.2: p=0.0002; Figure  252 2D). Importantly, despite these statistically significant differences, these results are derived from a 253 highly limited number of epitopes (12 and 18 altered epitopes derived from Delta and AY.4.2, 254 respectively, out of a total of 973 CD8 T cell recognized epitopes per variant). 255

To date, it is estimated that since the start of the pandemic there have been more than 400 million 258 COVID-19 cases (45). This translates to approximately 5% of the world population, however, many 259 cases were never included in the official statistics. In contrast, it is estimated that over half of the 260 world population (62.6% on February 25, 2022) has received at least one dose of a COVID-19 261 vaccine based on the reference SARS-CoV-2 sequence of the spike protein (46). Of all the proteins 262 encoded by SARS-CoV-2, the spike protein is subject to the highest rate of evolution (10). As a 263 consequence, spike protein-derived CD8 T cell recognized epitopes are inherently the least conserved 264

T cell epitopes of the SARS-CoV-2 proteome. Individuals that have not been infected but have only 265 received the vaccine may have a lower level of protective CD8 T cell immunity due to loss of the part 266 of the epitopes. 267

We performed our analysis on spike protein-derived epitopes only. The SARS-CoV-2 spike protein 268 encodes 263 previously identified CD8 T cell recognized epitopes. The majority of these 263 CD8 T 269 cell recognized epitopes is conserved across the variants included in our analysis (median: 95.1%, 270 range: 92.0-96.6%) corresponding to between 9 and 21 (median: 13) epitopes per variant which have 271 alterations in the amino acid sequence ( Figure 3A , Figure S1C , Supplementary Tables 2 and 3 ). The 272 majority (median 84%, range: 52-100%) of these mutated variant specific epitopes share at least 85% 273 similarity with the corresponding references epitopes ( Figure 3B and S2C) based on the IEDB 274 epitope clustering tool (median 89%, range: 71-100%; figure S2D ). 275

Interestingly, the mutated spike protein-derived epitopes from the Alpha, AY.4.2 and Omicron 276

variants are predicted to be significantly more immunogenic compared to reference (Alpha:  277 p=0.0034, AY.4.2: p=0.031, Omicron: p=0.0065; Figure 3C) . A large fraction of mutated epitopes 278 was predicted to be either more immunogenic (median: 63%, range: 22-79%) or unchanged in 279 immunogenicity (median: 20%, range: 11-31%). Between 6% and 67% (median: 15%) of variant 280 specific CD8 T cell recognized epitopes were predicted to be less immunogenic as a result of the 281 mutation ( Figure S3B ). Furthermore, for each included SARS-CoV-2 variant, decreased binding 282 affinity is predicted (≥2-fold change in IC50 value; Figure 3D ) for a subset of the altered epitopes 283 (median 48% of epitopes, range: 22%-75%). Between 25% and 59% (median: 44%) of altered 284 epitopes retained their predicted binding affinity (neutral; 0.5< fold change in IC50 <2), and between 285 0% and 25% (median: 6%) of altered epitopes had an increased predicted binding affinity (≤0. Figure 3E ). Importantly, despite 289 these statistically significant differences, these results are derived from only 8 to 14 (median: 12) 290 unique CD8 T cell recognized epitopes that are mutated per variant, out of a total of 263 unique 291 epitopes per variant. 292

Next, we tested whether variant-specific mutations may have a more profound effect on spike 293

protein-derived CD8 T cell recognized epitopes compared to non-spike. We performed the analysis 294 on non-spike protein-derived epitopes and compared these to the results above. As expected, a 295 smaller fraction of CD8 T cell recognized epitopes in the SARS-CoV-2 spike protein were found to 296

be conserved compared to those in non-spike proteins (median: 95.1%, range: 92.0-96.6%; versus 297 median: 98.9%, range: 98.0-99.2%; Figure S1C -D). All epitopes overlapping with multi-amino acid 298

substitutions, deletions and/or insertions except one were located in the SARS-CoV-2 spike protein 299

( Figure S1F-G) . Such multi-amino acid changes are expected to lead to a lower sequence similarity 300 between altered and reference epitopes. In line with this, there was a significantly lower sequence 301 similarity between mutated and reference CD8 T cell recognized epitopes in the spike protein, 302

compared to the single-amino acid mutations in non-spike proteins (in variants Delta, p=0.043; 303 AY.4.2, p=0.047; Omicron, p=0.028; Figure 4A ). 304

Across the investigated SARS-CoV-2 variants, the fraction of CD8 T cell recognized epitopes with 305 low (<85%) sequence similarity to reference epitopes was significantly higher in spike versus non-306 spike protein-derived epitopes (p=0.016, Figure 4B ). Additionally, mutations in the spike protein of 307 the Delta, Mu and AY.4.2 variants were more detrimental to predicted HLA binding affinity 308 compared to non-spike protein mutations (Delta: p=0.019, Mu: p=0.025, AY.4.2: p=0.030; Figure  309 4C). In accordance with this, the fraction of CD8 T cell recognized epitopes with decreased predicted 310 binding affinity was significantly higher in spike versus non-spike protein-derived epitopes across the 311 variants (p=0.016, Figure 4D ). However, despite these statistically significant differences, these 312 results are derived from a limited number of unique mutated CD8 T cell recognized epitopes per 313 variant. 314

The overrepresentation of altered CD8 T cell recognized epitopes with multiple amino acid changes, 315

insertions and deletions in the spike protein is clearly pronounced. Accordingly, these epitopes are 316 more profoundly affected in terms of epitope sequence similarity, predicted binding affinity and 317 immunogenicity compared to non-spike protein derived epitopes. These results may be unrelated to T 318 cell immunity and may be explained for example by the high rate of evolution of the spike protein 319 due to natural selection pressure by antibody responses. In line with this, a substantial part (median: 320 65%, range: 36-75%) of the unique spike protein-derived CD8 T cell recognized epitopes that 321 overlap mutations were located in key domains that are associated with cell attachment and are 322 antibody targets (N-terminal domain, NTD; receptor-binding domain, RBD; receptor-binding motif, 323 RBM; Figure 4E ). Moreover, they are primarily present on the surface of the spike protein, making 324 them accessible to host antibodies ( Figure 4F ). 325

After the initial SARS-CoV-2 outbreak, SARS-CoV-2 variants Alpha, Delta and Omicron have 327

replaced the previous variant as the globally dominant SARS-CoV-2 variant (31,32). This is the 328 result of accumulated mutations resulting in amino acid changes that have allowed these variants to 329 evade immunity in the general population. This notion is supported by for example data showing that 330 serum from vaccine-recipients is less effective at neutralizing SARS-CoV-2 variants Delta and 331

Omicron (23,24). The mutations do not appear to prevent general cross-recognition of SARS-CoV-2 332 variants by T cells induced by reference SARS-CoV-2 (25-29). However, systematic data regarding 333 the effect of SARS-CoV-2 variant-specific amino acid changes on the properties of the previously 334 recognized CD8 T cell epitopes has been lacking. 335

Our analyses revealed that the vast majority of both the spike (median: 95.1%, range: 92.0-96.6%) 336

and pan-proteome (median: 98.9%, range: 98.0-99.2%) derived CD8 T cell recognized epitopes were 337 conserved in the investigated SARS-CoV-2 variants. In accordance with the experimental data 338 described above, this suggests that memory T cell responses are not likely to be diminished upon re-339 infection by a different SARS-CoV-2 variant, or upon infection by one of the SARS-CoV-2 variants 340 after vaccination. In addition, for the minority of presented CD8 T cell recognized epitopes that is 341 altered by mutations, the high degree of sequence similarity to the reference epitopes will likely also 342 not prevent cross-recognition by memory CD8 T cells. 343

The finding that CD8 T cell epitopes from SARS-CoV-2 were generally conserved is in accordance 344

with the concept of antigenic drift. Antigenic drift driven by selective pressure from T cells is largely 345 irrelevant in acute viral infections such as SARS-CoV-2 due to the huge polymorphism of HLA loci 346 in a population and the diverse antigen repertoire these complexes present to T cells (9). Antigenic 347 drift is likely to have a stochastic influence on T cell epitopes -a 'bystander effect'. Our observations 348 are in line with this notion. First, for the minority of CD8 T cell recognized epitopes that overlap with 349 mutations, epitope sequences are generally conserved in terms of sequence similarity to the reference 350 sequence. Second, the majority (median: 55.6%, range: 46.2-78.6%) of these CD8 T cell recognized 351 epitopes are predicted to possess unchanged or even increased binding affinity to the HLA allele as a 352

result of the mutation. Third, the mutations in the CD8 T cell recognized epitopes in SARS-CoV-2 353 variants AY.4.2 and Omicron are predicted to result in more immunogenic, rather than less 354

immunogenic T cell epitopes. Fourth, many of the observed changes in predicted binding affinity and 355 sequence similarity of mutated CD8 T cell recognized epitopes in comparison to the reference 356 epitopes, are indeed driven by mutations in the spike protein. Finally, the majority (median: 65%, 357 range: 36-75%) of spike protein-derived CD8 T cell recognized epitopes that overlap with a mutation 358 are located in key domains that are frequently recognized by antibody responses and/or are involved 359 in cell attachment (10). Therefore, on the basis of our analysis and as expected, there is no indication 360 of T cell based selective pressure on SARS-CoV-2 leading to alteration of the CD8 T cell recognized 361 epitopes. 362

As SARS-CoV-2 derived T cell epitopes are not subject to substantial antigenic drift, T cells are 363 likely to remain consistent in their recognition of infected cells. However, the stochastic influence by 364 the mutations focused on the spike protein affects the ability of spike protein-derived T cell epitopes 365

to be presented to the immune system or to be recognized by previously induced T cell responses. 366

This is most pronounced for the SARS-CoV-2 variants Delta, AY.4.2 and Omicron, which are also 367 most efficient at escaping humoral immunity as a result of numerous mutations in the spike protein.

These variants also have the largest, albeit overall minor, negative effect on epitope presentation 369 relative to the other SARS-CoV-2 variants. By only targeting the spike protein, the vaccine induced 370

immunity is limited to SARS-CoV-2 T cell epitopes which are most prone to a 'bystander' effect as a 371

result of the high mutation rate of the spike protein. Even though the currently approved vaccines 372 only include the spike protein, our data suggest that T cell immunity can protect against severe 373 COVID-19. However, it does seem like a logical approach to develop next generation vaccines 374

incorporating other parts of the SARS-CoV-2 proteome which can lead to a broader T cell response 375

providing protection should the spike protein undergo further changes over time. 376

The authors declare that the research was conducted in the absence of any commercial or financial 378 relationships that could be construed as a potential conflict of interest. 379

Author Contributions 380 OI and SK performed the experiments, analyzed the data and wrote the manuscript. PK obtained the 381 funding and supervised the study. All authors contributed to the article and approved the submitted 382 version. 383

Funding 384

The project was funded with the Netherlands Cancer Institute Kvistborg group start-up funding. 385

The datasets analyzed for this study are included in the article/supplementary data. Further inquiries 387

can be directed to the corresponding author. 388 (whiskers), and all data points (single circles). Statistical significance was tested with a two-tailed 526

Wilcoxon matched-pairs signed rank test. Variation in numbers of epitopes in the analyses are due to 527

inclusion of epitopes binding one or more HLA restriction elements. * P < 0.05, *** P < 0.001. n 528

indicates the number of epitopes analyzed per group. 529 indicating the predicted binding affinity IC50 (nM) of the reference and altered spike protein-derived 543 CD8 T cell recognized epitope to the corresponding HLA restriction element. Box plots indicate the 544 median (line), 25th and 75th percentile (box), min and max (whiskers), and all data points (single 545 circles). Statistical significance was tested with a two-tailed Wilcoxon matched-pairs signed rank 546 test. Variation in numbers of epitopes in the analyses are due to inclusion of epitopes binding one or 547 more HLA restriction elements. AA: amino acid, DEL: deletion, INS: insertion. * P < 0.05, ** P < 548 0.01, *** P < 0.001. n indicates the number of epitopes analyzed per group. 549 in the open conformation with one erect RBD. Colors represent unique altered CD8 T cell recognized 565 epitopes overlapping with the indicated domains. Image produced with ChimeraX using PDB 566 accession: 6ZGG. Box plots indicate the median (line), 25th and 75th percentile (box), min and max 567 (whiskers), and all data points (single circles). Statistical significance was tested with a two-tailed 568

Mann-Whitney U test (A, C) or with a two-tailed Wilcoxon matched-pairs signed rank test (B, D). 569

Variation in numbers of epitopes in the analyses are due to inclusion of epitopes binding one or more 570 HLA restriction elements. * P < 0.05. n indicates the number of epitopes analyzed per group. 571

United by the global COVID-19 pandemic: divided by our values and viral identities

COVID-19 as a global challenge: towards an inclusive and sustainable future

Dating first cases of COVID-19

Dissecting the early COVID-19 cases in Wuhan

Mutation rate of SARS-CoV-2 and emergence of mutators during experimental evolution

RNA virus mutations and fitness for survival

Mechanisms of viral mutation

Rates of evolutionary change in viruses: patterns and determinants

Antigenic drift: Understanding COVID-19

SARS-CoV-2 variants, spike mutations and immune escape

The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages

Focused antibody response to influenza linked to antigenic drift

Defining influenza A virus hemagglutinin antigenic drift by sequential monoclonal antibody 415 selection

Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment

IL-6 and CD8+ T cell counts combined are an early 420 predictor of in-hospital mortality of patients with COVID-19

Clinical Outcome of COVID-19 Patients Using T Lymphocyte Subsets with 340 Cases from Wuhan

China: A Retrospective Cohort Study and a Web Visualization Tool

Persistent High 426 Percentage of HLA-DRCD38 CD8 T Cells Associated With Immune Disorder and Disease Severity of 427 COVID-19

Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and 430 early immune pathology distinguish severe COVID-19 from mild disease

Correlates of protection against SARS-CoV-2 in rhesus macaques

SARS-CoV-2 variants of concern as of 24

Nextstrain: real-time tracking of pathogen evolution

Reduced neutralisation of the Delta 442 (B.1.617.2) SARS-CoV-2 variant of concern following vaccination

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

T cell immune responses to SARS-CoV-2 and variants of concern (Alpha and Delta) in infected and 448 vaccinated individuals

Impact of SARS-CoV-2 variants on the total CD4 and CD8 T cell reactivity in infected or 451 vaccinated individuals

Recognition of Variants of Concern by Antibodies and T Cells Induced by 454 a SARS-CoV-2 Inactivated Vaccine

Effectiveness of ChAdOx1 nCoV-19 vaccine 457 against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-458 control study and a mechanistic study of post-vaccination immune responses

T cell responses to SARS-CoV-2 spike cross-recognize Omicron

SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants. Front 464 Immunol

disease and diplomacy: GISAID's innovative contribution to global 466 health

33. IEDB.org: Free epitope database and prediction resource

Cross-Reactivity and for "Holes" in the T Cell Repertoire

Development 474 of a novel clustering tool for linear peptide sequences

Properties of MHC Class I Presented Peptides That Enhance Immunogenicity

NetMHCpan-4.1 and NetMHCIIpan-4.0: improved 479 predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC 480 eluted ligand data

Global initiative on sharing all influenza data -from vision to reality

41. IEDB.org: Free epitope database and prediction resource

T Cell Cross-Reactivity and Conformational Changes during TCR 487 Engagement

Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ 490 T cell response

Identification and characterization of a SARS-CoV-2 specific CD8+ T cell 493 response with immunodominant features

COVID-19 situation update worldwide, as of week 7

Coronavirus Pandemic (COVID-19)